FDA Expands Indication for Platelet Booster Avatrombopag FDA Expands Indication for Platelet Booster Avatrombopag
Avatrombopag is now indicated for adults with thrombocytopenia and chronic immune thrombocytopenia; it is already approved for adults with thrombocytopenia and chronic liver disease.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer & Oncology | Hematology | Liver | Liver Disease | Thrombocytopenia | Urology & Nephrology